- Home
- GERN vs PCN Comparison
GERN vs PCN Comparison
Compare GERN & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- PCN
- Stock Information
- Founded
- GERN 1990
- PCN 2001
- Country
- GERN United States
- PCN United States
- Employees
- GERN N/A
- PCN N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- PCN Investment Managers
- Sector
- GERN Health Care
- PCN Finance
- Exchange
- GERN Nasdaq
- PCN Nasdaq
- Market Cap
- GERN 853.5M
- PCN 810.6M
- IPO Year
- GERN 1996
- PCN N/A
- Fundamental
- Price
- GERN $1.57
- PCN $12.74
- Analyst Decision
- GERN Buy
- PCN
- Analyst Count
- GERN 9
- PCN 0
- Target Price
- GERN $5.13
- PCN N/A
- AVG Volume (30 Days)
- GERN 13.0M
- PCN 218.7K
- Earning Date
- GERN 05-07-2025
- PCN 01-01-0001
- Dividend Yield
- GERN N/A
- PCN 9.73%
- EPS Growth
- GERN N/A
- PCN N/A
- EPS
- GERN N/A
- PCN N/A
- Revenue
- GERN $116,293,000.00
- PCN N/A
- Revenue This Year
- GERN $160.12
- PCN N/A
- Revenue Next Year
- GERN $55.01
- PCN N/A
- P/E Ratio
- GERN N/A
- PCN N/A
- Revenue Growth
- GERN 22264.04
- PCN N/A
- 52 Week Low
- GERN $1.17
- PCN $10.70
- 52 Week High
- GERN $5.34
- PCN $14.48
- Technical
- Relative Strength Index (RSI)
- GERN 51.71
- PCN 48.79
- Support Level
- GERN $1.30
- PCN $12.65
- Resistance Level
- GERN $1.54
- PCN $12.77
- Average True Range (ATR)
- GERN 0.11
- PCN 0.10
- MACD
- GERN 0.03
- PCN 0.00
- Stochastic Oscillator
- GERN 66.67
- PCN 61.54
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.